Mayo Clinic awarded major NIH contract for smallpox genomics research

October 04, 2004

ROCHESTER, Minn. -- Vaccine researchers at Mayo Clinic have been awarded a $10 million federal contract to study genetic susceptibility to smallpox and genomic-based risks to the smallpox vaccine. "This award underscores the confidence of the National Institutes of Health in our research capabilities and our track record, specifically our published research on vaccines for smallpox, anthrax and measles," said Gregory Poland, M.D., head of Mayo's Vaccine Research Group and lead researcher on the project. "This further strengthens Mayo Clinic's mission in improving and protecting the health of people worldwide."

The contract from the National Institute of Allergy and Infectious Diseases is for $10.2 million over five years and supports establishment and operation of a Population Genetics Analysis Program. The programs would investigate immune-response gene polymorphisms that affect an individual's susceptibility to infection, as well as their response to vaccination. Researchers also will study potential cellular and hormonal responses to smallpox vaccination.

Dr. Poland says Mayo Clinic's research expertise was a factor in the NIAID decision. "A major strength is our 12 years of experience in performing exactly these types of studies with other live viral vaccine models."

Mayo Clinic's resources as a genomics research center will also be integral in the effort. Genotyping of genomic DNA will be performed by the Mayo Genotyping Share Resource (GSR), a core laboratory under the direction of co-investigator Julie Cunningham, Ph.D. Other aspects of the research including bioinformatics -- the processing of the huge number of data points in this type of genomic research -- will involve Mayo biostatisticians and the Mayo Advanced Genomics Technology Center (AGTC).

"This award to Dr. Poland is another tangible confirmation that Mayo is fast becoming a leader in applying the tools of Genomics to the most pressing issues in the prevention, diagnosis and treatment of disease," said Eric Wieben, Ph.D., Director of the Mayo Genomics Research Center. The center is responsible for developing the AGTC.

The smallpox vaccine investigation is to begin immediately.
-end-
To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories. For more information about research at Mayo Clinic, go to www.mayo.edu/research.

Mayo Clinic

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.